Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients

Letter Surgery

Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants

Nicholas W. Lange et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Article Multidisciplinary Sciences

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Lihong Liu et al.

Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.

NATURE (2022)

添加到收藏夹

Article Medicine, General & Internal

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

R. L. Gottlieb et al.

Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Surgery

Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: A nationwide population-based study

Silvia Trapani et al.

Summary: Italy has set up a dedicated surveillance system for COVID-19 cases, revealing higher infection and mortality rates in solid organ transplant recipients, especially in the Lombardy region. Heart transplant recipients have a higher infection rate, while liver transplant recipients have a lower rate. Further studies on disease management and evolution are needed for these high-risk patients.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

添加到收藏夹

Article Immunology

A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients

Matthew Ringer et al.

Summary: This retrospective study found no significant differences in disease severity and mortality between solid organ transplant (SOT) patients with Coronavirus Disease 2019 (COVID-19) and non-SOT patients. More SOT patients received tocilizumab and steroids, indicating the need for larger studies to confirm these findings. The analysis of key interleukin levels contributes to understanding the complex cytokine release syndrome in COVID-19.

TRANSPLANT INFECTIOUS DISEASE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen et al.

Summary: PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor, has been discovered with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. This new drug has shown promise in countering the threat of COVID-19 with its oral activity and safety in clinical trials.

SCIENCE (2021)

添加到收藏夹

Article Immunology

Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network

Yousaf B. Hadi et al.

Summary: Solid organ transplant recipients have a higher risk of hospitalization and acute kidney injury in COVID-19, but this increased risk is mainly due to a higher burden of comorbidities.

TRANSPLANTATION (2021)

添加到收藏夹

Review Immunology

The association between severe or death COVID-19 and solid organ transplantation: A systematic review and meta-analysis

Guangyu Ao et al.

Summary: The results of this study indicate that solid organ transplant recipients with COVID-19 have a higher risk of COVID-19 severity and mortality compared to the general population.

TRANSPLANTATION REVIEWS (2021)

添加到收藏夹

Article Surgery